Counting the cost of public and philanthropic R&D funding: the case of olaparib
Background Lack of transparency around manufacturing costs, who bears the bulk of research and development costs and how total costs relate to the pricing of products, continue to fuel debates. This paper considers the case of olaparib (Lynparza®), recently indicated for use among BRCA-mutant breast...
Gardado en:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Taylor & Francis Group
2022-12-01
|
| Series: | Journal of Pharmaceutical Policy and Practice |
| Assuntos: | |
| Acceso en liña: | http://dx.doi.org/10.1186/s40545-022-00445-9 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|